Mirvaso (brimonidine tartrate) NDC 0299-5980

NDC codes

FDA NDC Directory

Product NDC (as listed)0299-5980Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00299-5980Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
0299-5980-00	00299598000	1 TUBE in 1 BLISTER PACK (0299-5980-00) / 2 g in 1 TUBEMarketed from Aug 23, 2013 · Sample package
0299-5980-02	00299598002	2 g in 1 TUBE (0299-5980-02)Marketed from Aug 23, 2013 · Sample package
0299-5980-30	00299598030	30 g in 1 TUBE (0299-5980-30)Marketed from Aug 23, 2013
0299-5980-35	00299598035	1 BOTTLE, PUMP in 1 CARTON (0299-5980-35) / 30 g in 1 BOTTLE, PUMPMarketed from Aug 23, 2013
0299-5980-45	00299598045	45 g in 1 TUBE (0299-5980-45)Marketed from Aug 23, 2013

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Mirvaso
Generic name (nonproprietary): brimonidine tartrate
Active ingredients: Brimonidine tartrate — 5 mg/g
Dosage form: Gel
Route: Topical
Labeler: Galderma Laboratories, L.P.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 204708
Marketing start: Aug 23, 2013
Listing expires: Dec 31, 2026
Other FDA classes: Adrenergic alpha-Agonists (Mechanism)
Identifiers: Product ID 0299-5980_253bf4a2-3c4d-f4af-e063-6394a90a0b0aSPL ID 253bf4a2-3c4d-f4af-e063-6394a90a0b0aSPL set ID f6a4353f-ae69-4214-901f-e5d42a6fbde7RxCUI 1437707, 1437709UNII 4S9CL2DY2H
Pharmacologic class: alpha-Adrenergic Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Topical products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400299598000 followed by a unit qualifier and the quantity

Package 00299-5980-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 24, 2024.

Indications (excerpt from the label)

MIRVASO (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) erythema of rosacea in adults 18 years of age or older. MIRVASO (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older.( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)